Analysts Set Expectations for INKT FY2030 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for MiNK Therapeutics in a report issued on Wednesday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of $1.31 for the year. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

Separately, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Up 0.4%

Shares of INKT opened at $10.57 on Thursday. MiNK Therapeutics has a 52-week low of $6.34 and a 52-week high of $76.00. The stock has a fifty day simple moving average of $10.92 and a two-hundred day simple moving average of $12.23. The company has a market capitalization of $49.57 million, a PE ratio of -3.56 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.14.

Institutional Trading of MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent quarter. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.